Continuous Glucose Monitorization in Hospitalized Patients With COVID-19

Diabetes Mellitus Clinical Trial

Official title:

Assessment of the Effect of Continuous Glucose Monitorization on Glycemic Variability and Insulin's Prescription in Hospitalized Patients With COVID-19

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05096858
• Other study ID #: 3066
• Status: Recruiting
• Start date: June 1, 2020
• Est. completion date: July 31, 2024

Study information

• Verified date: September 2023
• Source: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
• Contact: ALFONSO GULIAS HERRERO
• Phone: 523123173679
• Email: alfonso.guliash[@]incmnsz.mx
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

DM2 is a major comorbidity of COVID-19. It has been observed that subjects with DM2 require more medical interventions, have a significantly higher mortality (7.8% versus 2.7%) and injuries of multiple organs that the individuals not diabetics.

In situations of glycemic variability, phenomena of oxidative stress and activation of protein kinase C can be initiated , through the release of pro-inflammatory cytosines , which could induce microvascular damage .Patients with diabetes and COVID-19 were shown to be more likely to develop serious or critical illness with more complications, and to have higher incidence rates of antibiotic therapy, non-invasive and invasive mechanical ventilation, and death (11.1% vs. 4.1%).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 120
• Est. completion date: July 31, 2024
• Est. primary completion date: June 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 100 Years

Eligibility

Inclusion Criteria:

• Confirmed COVID-19 pneumonia

• Diabetes mellitus

Exclusion Criteria:

• Less than 3 days of hospital care

Related Conditions & MeSH terms

• COVID-19
• Covid19
• Diabetes Mellitus

Locations

Country	Name	City	State
Mexico	National Institute of Medical Sciences and Nutrition Salvador Zubiran	Mexico City

Sponsors (1)

Lead Sponsor	Collaborator
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

Country where clinical trial is conducted

Mexico, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Glucose variability	Percentage of time within the ADA recommended range	For up to two weeks, during hospitalization
Primary	Insulin use	Average daily UI of insulin per patient	For up two weeks, during hospitalization